Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep 2:5:429.
doi: 10.1186/1752-1947-5-429.

Atypical presentations and rare metastatic sites of renal cell carcinoma: a review of case reports

Petros Sountoulides  1 , Linda Metaxa, Luca Cindolo
Affiliations

Atypical presentations and rare metastatic sites of renal cell carcinoma: a review of case reports

Petros Sountoulides et al. J Med Case Rep. .

Abstract

Renal cell carcinoma is a potentially lethal cancer with aggressive behavior and a propensity for metastatic spread. Due to the fact that the patterns of metastases from renal cell carcinomas are not clearly defined, there have been several reports of cases of renal cell carcinoma associated with rare metastatic sites and atypical presenting symptoms. The present review focuses on these atypical rare clinical presentations of renal cell carcinomas both at the time of diagnosis of the primary tumor but also in the years after radical nephrectomy.

PubMed Disclaimer

References

    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics 2006. CA Cancer J Clin. 2006;56(2):106–130. doi: 10.3322/canjclin.56.2.106. - DOI - PubMed
    1. Chen DY, Uzzo RG. Evaluation and management of the renal mass. Med Clin North Am. 2011;95(1):179–189. doi: 10.1016/j.mcna.2010.08.021. - DOI - PubMed
    1. Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol. 2009;36(Suppl 3):S26–36. - PubMed
    1. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281. doi: 10.1056/NEJMoa066838. - DOI - PubMed
    1. Mekhail TM, Abou-Jawde RM, Boumerhi G Malhi S, Wood L, Elson P, Bukowski R. Validation and extension of the Memorial Sloan Kettering prognostic factors model for survival in patients with previously untreated renal metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832–841. doi: 10.1200/JCO.2005.05.179. - DOI - PubMed

LinkOut - more resources